“Village Seeks Dissolution Study (East Aurora Advertiser)” plus 3 more |
- Village Seeks Dissolution Study (East Aurora Advertiser)
- Town and Village will Study Highway/DPW Merger (East Aurora Advertiser)
- Anthera Pharmaceuticals reaches agreement with the FDA on SPA for VISTA-16 clinical study (News-Medical-Net)
- Insulin study could lead to new dosage devices (Manila Bulletin via Yahoo! Philippines News)
Village Seeks Dissolution Study (East Aurora Advertiser) Posted: 08 Feb 2010 08:28 AM PST Message from fivefilters.org: If you can, please donate to the full-text RSS service so we can continue developing it. Village Pursues Solar Power for DPW Facility Town and Village will Study Highway/DPW Merger 2009 Candidates Discuss Campaign Financial Disclosure Iroquois will Host Cavalcade of Bands Wales Looks at Ways to Abolish Tax Post West Declares Candidacy for Village Board A Classic Winter Week in East Aurora Village Seeks Dissolution Study Man Charged with DWI Tried to Flee Troopers Deputies Make Reckless Driving Arrest in Holland Wales Kiwanians Plan "Souper Bowl" Event Farm Bureau Recognizes Officials Pathways Christian Fellowship and Local Residents to Assist in Gulf Coast Rebuilding Efforts Bachman Wins Middle School Geography Bee Committee Members Sought for Elma Day Unshackle Upstate Leader Coming to East Aurora Wales Makes 2010 Appointments Marilla Club Celebrates 95th Anniversary of Kiwanis Classes Aimed at Needs of Single Parents Town Board to Discuss Joint Facility Feb. 16 Holland School OKs Budget, Teachers' Contract Judicial Race had the Highest Spending of 2009 EA Students Prepare for "Annie" Travel Info Links Five Filters featured article: Chilcot Inquiry. Available tools: PDF Newspaper, Full Text RSS, Term Extraction. | |
Town and Village will Study Highway/DPW Merger (East Aurora Advertiser) Posted: 08 Feb 2010 08:29 AM PST Message from fivefilters.org: If you can, please donate to the full-text RSS service so we can continue developing it. Village Pursues Solar Power for DPW Facility Town and Village will Study Highway/DPW Merger 2009 Candidates Discuss Campaign Financial Disclosure Iroquois will Host Cavalcade of Bands Wales Looks at Ways to Abolish Tax Post West Declares Candidacy for Village Board A Classic Winter Week in East Aurora Village Seeks Dissolution Study Man Charged with DWI Tried to Flee Troopers Deputies Make Reckless Driving Arrest in Holland Wales Kiwanians Plan "Souper Bowl" Event Farm Bureau Recognizes Officials Pathways Christian Fellowship and Local Residents to Assist in Gulf Coast Rebuilding Efforts Bachman Wins Middle School Geography Bee Committee Members Sought for Elma Day Unshackle Upstate Leader Coming to East Aurora Wales Makes 2010 Appointments Marilla Club Celebrates 95th Anniversary of Kiwanis Classes Aimed at Needs of Single Parents Town Board to Discuss Joint Facility Feb. 16 Holland School OKs Budget, Teachers' Contract Judicial Race had the Highest Spending of 2009 EA Students Prepare for "Annie" Travel Info Links Five Filters featured article: Chilcot Inquiry. Available tools: PDF Newspaper, Full Text RSS, Term Extraction. | |
Posted: 08 Feb 2010 05:01 AM PST Message from fivefilters.org: If you can, please donate to the full-text RSS service so we can continue developing it. Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, announced today that it reached an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the Phase 3 clinical study named VISTA-16 (Vascular Inflammation Suppression to Treat Acute Coronary Syndrome - 16 Weeks) for its lead product candidate, A-002, an oral sPLA2 inhibitor, in combination with HMG-CoA reductase inhibitor, or statin, therapy for short-term (16-week) treatment of patients experiencing an acute coronary syndrome. This pivotal study, which is expected to begin in the first half of this year and to be completed 18 months thereafter, is expected to enroll up to 6,500 patients. Patients will be randomized within 96 hours of an acute coronary syndrome and will receive 16 weeks of either once-daily of A-002 or placebo in addition to a dose of atorvastatin. In addition, Anthera today announced that it has appointed Daniel K. Spiegelman to its Board of Directors and as Chairman of the Audit Committee of the Board of Directors. Mr. Spiegelman provides management and financial consulting services to biotechnology companies. From 1998 to 2009, Mr. Spiegelman served as Senior Vice President and Chief Financial Officer of CV Therapeutics, Inc., a biopharmaceutical company that was acquired by Gilead Sciences, Inc. in 2009. From 1991 to 1998, Mr. Spiegelman served at Genentech, Inc., most recently as Treasurer. Mr. Spiegelman also serves on the board of directors of Affymax, Inc., Cyclacel Pharmaceuticals, Inc., Omeros Corporation and Oncothyreon, Inc., all publicly traded biopharmaceutical companies. Mr. Spiegelman holds a B.A. in economics from Stanford University and an M.B.A. from the Stanford Graduate School of Business. SOURCE Anthera PharmaceuticalsFive Filters featured article: Chilcot Inquiry. Available tools: PDF Newspaper, Full Text RSS, Term Extraction. | |
Insulin study could lead to new dosage devices (Manila Bulletin via Yahoo! Philippines News) Posted: 07 Feb 2010 04:04 PM PST Message from fivefilters.org: If you can, please donate to the full-text RSS service so we can continue developing it. The results of a new study on managing juvenile diabetes may give hope to millions of parents in this country and abroad who typically wake up several times a night to make sure their children's blood sugar levels have not dropped into the danger zone. Researchers are trying to pair such systems with automated glucose testing. And the research, published Friday in The Lancet, a British medical journal, could help spur medical device companies to more quickly develop technology based on the study's underlying concept. The study reported that a novel computer algorithm that analyzed children's glucose levels and recommended frequent adjustments in their insulin doses was better at preventing very low glucose overnight than a standard diabetes management system. That standard system involved a continuous glucose monitor that operated separately from a preprogrammed insulin pump - an approach now used by many of the estimated three million people nationwide who have Type 1 diabetes. Type 1 diabetes, also known as juvenile diabetes, is a disease that often develops early in life and is separate from Type 2 diabetes, which often stems from obesity. Very low glucose, called hypoglycemia, is a condition that poses risks for people with either form of diabetes, potentially causing shakiness, dizziness, seizures, coma or even death. But it is a particular concern among children on insulin because their blood sugar levels tend to fluctuate more widely, researchers said. No children in the study who were treated with the computer-assisted system experienced very low blood sugar overnight. But there were nine instances of very low blood sugar among children who had the standard treatment, according to the study, conducted by researchers in Britain at the University of Cambridge. "This is an important step in diabetes control because it shows that, with this system, people can sleep safely with minimized risk of hypoglycemia," said Dr. Eric Renard, a professor of diabetology at Montpellier University Hospital in Montpellier, France. Dr. Renard, whose commentary accompanied the study in The Lancet, has been a consultant and speaker for several makers of diabetic products, he said. Industry analysts have estimated that 10 to 15 percent of Americans with Type 1 diabetes - perhaps 400,000 of them - use either a continuous glucose monitor or an insulin pump, or in some cases both. Over the last decade, the makers of medical devices have developed techniques that have widened diabetes management options beyond pricking the finger several times a day to test blood glucose levels. Companies like DexCom in San Diego now make small continuous glucose monitors whose sensors can be embedded in the skin. And Animas, a division of Johnson & Johnson, makes programmable pumps the size of a cellphone that administer insulin doses through a tiny implantable catheter. (NYT) Five Filters featured article: Chilcot Inquiry. Available tools: PDF Newspaper, Full Text RSS, Term Extraction. |
You are subscribed to email updates from Yahoo! News Search Results for Study Techniques To stop receiving these emails, you may unsubscribe now. | Email delivery powered by Google |
Google Inc., 20 West Kinzie, Chicago IL USA 60610 |
No comments:
Post a Comment